

CITATION REPORT

List of articles citing

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia

DOI: 10.1056/nejmoa1203859

New England Journal of Medicine, 2012, 367, 309-18.

Source: <https://exaly.com/paper-pdf/53577501/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
743	Do omega-3 Fatty acids have a role in prevention of cardiovascular disease?. 2012 , 3, 395		2
742	Omega-3 fatty acids and coronary heart disease. The final verdict?. 2012 , 23, 554-9		20
741	Current world literature. 2012 , 23, 576-9		
740	The fats of life in diabetes. 2012 , 12, 216-220		3
739	Diabetes: basal insulin and n-3 fatty acids--no effect on cardiovascular outcomes. 2012 , 8, 446		1
738	n-3 fatty acids and cardiovascular outcomes in dysglycemia. <i>New England Journal of Medicine</i> , 2012 , 367, 1760; author reply 1761	59.2	4
737	Effects of Therapeutic Lifestyle Change diets high and low in dietary fish-derived FAs on lipoprotein metabolism in middle-aged and elderly subjects. 2012 , 53, 1958-67		27
736	Placing the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial in context. 2012 , 17, 118-120		
735	Diabetes: Does glycemic control reduce cardiovascular event rates?. 2012 , 9, 434		1
734	Omega-3-Fettsäuren wirkungslos. 2012 , 6, 25-25		
733	Omega 3 Fatty acids and cardiovascular outcomes: systematic review and meta-analysis. 2012 , 5, 808-18		152
732	Omega-3 fatty acids and cardioprotection-IIb or not IIb?. 2012 , 380, 1976-7		1
731	Ω3 fatty acids, linolenic acid, and antioxidants: immunomodulators or inert dietary supplements?. 2012 , 16, 325		11
730	Hot topics in cardiology: data from IABP-SHOCK II, TRILOGY-ACS, WOEST, ALTITUDE, FAME II and more. 2012 , 101, 861-74		5
729	Association between fish consumption, long chain omega 3 fatty acids, and risk of cerebrovascular disease: systematic review and meta-analysis. 2012 , 345, e6698		246
728	Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. 2012 , 308, 1024-33		733
727	Early insulin treatment in type 2 diabetes: ORIGINAL sin or valuable choice as ORIGINAL treatment? An open debate on the ORIGIN study results. 2012 , 22, 1007-12		9

726	Kardiovaskuläres Risiko und medikamentöse Lipidtherapie. 2012 , 8, 568-572		
725	Neue Entwicklungen in der Lipidtherapie. 2012 , 8, 573-578		
724	Basal insulin and cardiovascular and other outcomes in dysglycemia. <i>New England Journal of Medicine</i> , 2012 , 367, 319-28	59.2	1138
723	SECONDARY PHARMACOLOGICAL PREVENTION OF CARDIOVASCULAR DISEASES: OUR ABILITY IN CLINICAL PRACTICE. 2012 , 8, 788-797		
722	Nutritional supplements. 2012 , 55, 889		3
721	Omega-3 index and prognosis in acute coronary chest pain patients with a low dietary intake of omega-3. 2013 , 47, 69-79		3
720	Recent findings on the health effects of omega-3 fatty acids and statins, and their interactions: do statins inhibit omega-3?. 2013 , 11, 5		33
719	Behavioral interventions for antipsychotic induced appetite changes. 2013 , 15, 347		17
718	Predictive power of cell-to-cell variability. 2013 , 1, 131-139		19
717	Setting the record straight on TIDE: a lost opportunity for patients with diabetes. 2013 , 56, 1884-7		1
716	Empfehlungen der Projektgruppe Prävention der DGK zur risikoadjustierten Prävention von Herz- und Kreislauferkrankungen. 2013 , 7, 141-156		
715	Omega-3 polyunsaturated fatty acids in the treatment of atherogenic dyslipidemia. 2013 , 14, 237-42		21
714	Nutrient reference values for bioactives: new approaches needed? A conference report. 2013 , 52 Suppl 1, 1-9		218
713	Ernährungstherapie des Typ-2-Diabetes. 2013 , 9, 405-416		3
712	Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management. 2013 , 73, 327-39		141
711	Therapie nutritionnelle. 2013 , 37, S409-S421		2
710	Nutrition therapy. 2013 , 37 Suppl 1, S45-55		90
709	Current evidence and future perspectives on n-3 PUFAs. 2013 , 170, S3-7		21

708	Fish oil-enriched diet protects against ischemia by improving angiogenesis, endothelial progenitor cell function and postnatal neovascularization. 2013 , 229, 295-303	30
707	Omega-3 polyunsaturated fatty acids in the treatment of hypertriglyceridaemia. 2013 , 170, S16-20	26
706	Common variants associated with plasma triglycerides and risk for coronary artery disease. 2013 , 45, 1345-52	597
705	Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options. 2013 , 230, 381-9	52
704	Lipids and the endothelium: bidirectional interactions. 2013 , 15, 365	28
703	Omega-3 fatty acid blood levels: clinical significance and controversy. 2013 , 128, 2154-61	76
702	Nutritional recommendations for cardiovascular disease prevention. 2013 , 5, 3646-83	122
701	Food and dietary pattern-based recommendations: an emerging approach to clinical practice guidelines for nutrition therapy in diabetes. 2013 , 37, 51-7	37
700	Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study. 2013 , 12, 100	51
699	n-3 fatty acids and cardiovascular disease: the story is not over yet. 2013 , 25, 357-63	5
698	Cardiovascular risk and lipid management beyond statin therapy: the potential role of omega-3 polyunsaturated fatty acid ethyl esters. 2013 , 8, 329-344	2
697	Emerging approaches for the treatment of hypertriglyceridemia. 2013 , 14, 1869-73	5
696	The effects of omega-3 polyunsaturated fatty acids on cardiac rhythm: a critical reassessment. 2013 , 140, 53-80	46
695	Demystifying the management of hypertriglyceridaemia. 2013 , 10, 648-61	75
694	Glycerol and fatty acids in serum predict the development of hyperglycemia and type 2 diabetes in Finnish men. 2013 , 36, 3732-8	97
693	[Update: clinical lipidology]. 2013 , 155, 49-52; quiz 53-4	1
692	Dietary linolenic acid increases the platelet count in ApoE ^{-/-} mice by reducing clearance. 2013 , 122, 1026-33	9
691	Fish oil for prevention of sudden death in hemodialysis patients?. 2013 , 83, 993-5	3

690	Results of a reevaluation of cardiovascular outcomes in the RECORD trial. 2013 , 166, 240-249.e1	128
689	Omega-3 supplementation and cardiovascular disease, acupuncture and chronic obstructive pulmonary disease (COPD), myofascial physical therapy and interstitial cystitis, and yoga and chronic pain. 2013 , 9, 54-7	4
688	n-3 PUFAs in cardiovascular disease. 2013 , 170, S33-8	17
687	Substituting non-HDL cholesterol with LDL as a guide for lipid-lowering therapy increases the number of patients with indication for therapy. 2013 , 226, 471-5	16
686	Long-chain omega-3 fatty acids: time to establish a dietary reference intake. 2013 , 71, 692-707	87
685	Rosiglitazone and cardiovascular outcomes: is there a clear answer?. 2013 , 128, 777-9	2
684	High-density lipoprotein subfractions--what the clinicians need to know. 2013 , 124, 116-25	81
683	Serum n-3 and n-6 polyunsaturated fatty acid profile as an independent predictor of cardiovascular events in hemodialysis patients. 2013 , 62, 568-76	55
682	Association between ratio of serum eicosapentaenoic acid to arachidonic acid and risk of cardiovascular disease: the Hisayama Study. 2013 , 231, 261-7	72
681	Red blood cell fatty acid levels improve GRACE score prediction of 2-yr mortality in patients with myocardial infarction. 2013 , 168, 53-9	48
680	Comparison of predictive performance of various fatty acids for the risk of cardiovascular disease events and all-cause deaths in a community-based cohort. 2013 , 230, 140-7	21
679	The association of n-3 fatty acids with serum High Density Cholesterol (HDL) is modulated by sex but not by Inuit ancestry. 2013 , 226, 281-5	7
678	Intake of traditional Inuit diet vary in parallel with inflammation as estimated from YKL-40 and hsCRP in Inuit and non-Inuit in Greenland. 2013 , 228, 496-501	12
677	The year in atherothrombosis. 2013 , 62, 1131-43	20
676	Pharmacologic interactions of multidrug therapy for dyslipidemia. 2013 , 15, 303	1
675	Emerging importance of omega-3 fatty acids in the innate immune response: molecular mechanisms and lipidomic strategies for their analysis. 2013 , 57, 1390-400	39
674	The role of marine n-3 fatty acids in improving cardiovascular health: a review. 2013 , 4, 357-65	45
673	Omega-3 Fatty acids and mortality outcome in patients with and without type 2 diabetes after myocardial infarction: a retrospective, matched-cohort study. 2013 , 35, 40-51	27

- 672 Beyond statins: lipid management to reduce cardiovascular risk. **2013**, 33, 754-64 13
- 671 Current evidence and future perspectives of omega-3 polyunsaturated fatty acids for the prevention of cardiovascular disease. **2013**, 706, 1-3 8
- 670 Platelet redox balance in diabetic patients with hypertension improved by n-3 fatty acids. **2013**, 36, 998-1005 15
- 669 n-3 fatty acids in patients with multiple cardiovascular risk factors. *New England Journal of Medicine*, **2013**, 368, 1800-8 59.2 383
- 668 Comparative cardiometabolic effects of fibrates and omega-3 fatty acids. **2013**, 167, 2404-11 6
- 667 Omega-3 and omega-6 fatty acids and type 2 diabetes. **2013**, 13, 279-88 24
- 666 Stearidonic and Elinolenic acids in echium oil improves glucose disposal in insulin resistant monkeys. **2013**, 89, 39-45 13
- 665 The need for combination drug therapies in patients with complex dyslipidemia. **2013**, 15, 391 7
- 664 Peroxidized unsaturated fatty acids stimulate Toll-like receptor 4 signaling in endothelial cells. **2013**, 92, 984-92 10
- 663 Fish in the diet: A review. **2013**, 38, 128-177 65
- 662 Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis. **2013**, 346, e8707 323
- 661 [Update dyslipidemia]. **2013**, 54, 1089-103 1
- 660 Moderne Fettstoffwechseltherapie bei Patienten mit Diabetes mellitus - Was ist neu?. **2013**, 11, 156-160
- 659 Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. **2013**, 34, 3137-44 167
- 658 Fettstoffwechselstörungen. **2013**, 09, 55-66
- 657 n-3 fatty acids in patients with cardiac risk factors. *New England Journal of Medicine*, **2013**, 369, 781-2 59.2 5
- 656 Revising common beliefs in the management of stable CAD. **2013**, 10, 65-6 7
- 655 Dietary polyunsaturated fatty acids and inflammation: the role of phospholipid biosynthesis. **2013**, 14, 21167-88 97

654	Replacement of reduced highly unsaturated fatty acids (HUFA deficiency) in dilative heart failure: dosage of EPA/DHA and variability of adverse peroxides and aldehydes in dietary supplement fish oils. 2013 , 125, 223-31	10
653	Oxidation of marine omega-3 supplements and human health. 2013 , 2013, 464921	81
652	The effects of n-3 long-chain polyunsaturated fatty acid supplementation on biomarkers of kidney injury in adults with diabetes: results of the GO-FISH trial. 2013 , 36, 1462-9	32
651	Do omega-3 polyunsaturated Fatty acids prevent cardiovascular disease? A review of the randomized clinical trials. 2013 , 6, 13-20	19
650	Omega-3 fatty acids and cardiovascular disease: new developments and applications. 2013 , 125, 100-13	63
649	Nutraceuticals and coronary heart disease. 2013 , 28, 475-82	13
648	Dietary fatty acids and lipoprotein metabolism: new insights and updates. 2013 , 24, 192-7	34
647	Are n-3 fatty acids still cardioprotective?. 2013 , 16, 141-9	48
646	Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN-GRACE). 2013 , 36, 2466-74	35
645	Characteristics associated with maintenance of mean A1C. 2013 , 36, 2915-22	21
644	Endothelial dysfunction in diabetes: pathogenesis, significance, and treatment. 2013 , 10, 133-56	80
643	Association of total marine fatty acids, eicosapentaenoic and docosahexaenoic acids, with aortic stiffness in Koreans, whites, and Japanese Americans. 2013 , 26, 1321-7	8
642	Role of dyslipidemia in patients with chronic kidney disease. 2013 , 125, 28-37	4
641	Omega-3 fatty acid therapy reduces triglycerides and interleukin-6 in hypertriglyceridemic HIV patients. 2013 , 14, 530-9	22
640	Do differences in risk factors explain the lower rates of coronary heart disease in Japanese versus U.S. women?. 2013 , 22, 966-77	8
639	What is wrong with meta-analysis? The importance of clinical heterogeneity in myocardial regeneration research. 2013 , 67, 1081-5	6
638	Is the tide going out on fish oil supplements for CVD?. 2013 , 24, 48-50	
637	Diet and cardiovascular disease: Dietary patterns, foods and nutrients. 2013 , 70, 170-171	6

636	Icosapent ethyl for the treatment of hypertriglyceridemia. 2013 , 14, 1409-16	13
635	Nutrition therapy recommendations for the management of adults with diabetes. 2013 , 36, 3821-42	395
634	Optimal use of lipid-altering therapy: guidelines versus evidence. 2013 , 8, 269-272	
633	Fatty acids and other risk factors for sudden cardiac death in patients starting hemodialysis. 2013 , 38, 12-8	20
632	Dietary intake of n-3 long-chain polyunsaturated fatty acids and risk of myocardial infarction in coronary artery disease patients with or without diabetes mellitus: a prospective cohort study. 2013 , 11, 216	18
631	Fish oil selectively improves heart function in a mouse model of lipid-induced cardiomyopathy. 2013 , 61, 345-54	8
630	The Year in Cardiology 2012: focus on cardiovascular disease prevention. 2013 , 34, 314-7	6
629	Fish oils, coronary heart disease, and the environment. 2013 , 103, 1568-76	16
628	Association between triglycerides and cardiovascular events in primary populations: a meta-regression analysis and synthesis of evidence. 2013 , 9, 671-80	24
627	[Diabetes mellitus related common medical disorders: recent progress in diagnosis and treatment. Topics: I. Pathophysiology, diagnosis and treatment; 11. Atherosclerosis]. 2013 , 102, 902-6	
626	Management of Hypertriglyceridemia for Prevention of Cardiovascular Diseases. 2013 , 2, 53	2
625	Exploratory analysis on the use of statins with or without n-3 PUFA and major events in patients discharged for acute myocardial infarction: an observational retrospective study. 2013 , 8, e62772	17
624	Change of heart: Mixed evidence on omega-3 FAs. 2013 , 19, 29	
623	Evidence-based diabetes nutrition therapy recommendations are effective: the key is individualization. 2014 , 7, 65-72	54
622	Grain and bean lysates improve function of endothelial progenitor cells from human peripheral blood: involvement of the endogenous antioxidant defenses. 2014 , 9, e109298	21
621	Effects of eicosapentaenoic acid on the levels of inflammatory markers, cardiac function and long-term prognosis in chronic heart failure patients with dyslipidemia. 2014 , 21, 712-29	28
620	Diabetic Dyslipidemia - Role of Saroglitazar. 2014 , 4,	1
619	Nutrition therapy recommendations for the management of adults with diabetes. 2014 , 37 Suppl 1, S120-43	441

618	N-3 fatty acids for prevention of cardiovascular disease. 2014 , 16, 450		24
617	Omega-3 Fatty Acid Blood Levels Clinical Significance Update. <i>Current Cardiovascular Risk Reports</i> , 2014 , 8, 407	0.9	40
616	Perspectives on a new prescription omega-3 fatty acid, icosapent ethyl, for hypertriglyceridemia. 2014 , 9, 149-161		4
615	Pitfalls in the use of randomised controlled trials for fish oil studies with cardiac patients. 2014 , 112, 812-20		40
614	Effect of ω 3 fatty acid ethyl esters on apolipoprotein B-48 kinetics in obese subjects on a weight-loss diet: a new tracer kinetic study in the postprandial state. 2014 , 99, E1427-35		21
613	Omega-3 polyunsaturated fatty acids and cardiovascular disease: an emphasis on omega-3-acid ethyl esters 90 for the treatment of hypertriglyceridemia. 2014 , 12, 1261-8		5
612	Fibrates and niacin: is there a place for them in clinical practice?. 2014 , 15, 2673-80		8
611	Krill oil for cardiovascular risk prevention: is it for real?. 2014 , 49, 907-12		11
610	Got Organic Milk?. 2014 , 31, 46-46		
609	Nutritional management of type 2 diabetes mellitus and obesity and pharmacologic therapies to facilitate weight loss. 2014 , 126, 139-52		11
608	Long chain n-3 polyunsaturated fatty acids and incidence rate of coronary artery calcification in Japanese men in Japan and white men in the USA: population based prospective cohort study. 2014 , 100, 569-73		39
607	Role of Glitazars in atherogenic dyslipidemia and diabetes: Two birds with one stone?. 2014 , 18, 283-7		9
606	The percentage of DHA in erythrocytes can detect non-adherence to advice to increase EPA and DHA intakes. 2014 , 111, 270-8		27
605	Combination therapy with statins: who benefits?. <i>Endocrinology and Metabolism Clinics of North America</i> , 2014 , 43, 993-1006	5.5	1
604	Dietary guidelines: Scientific substantiation and public health impact. 2014 , 39, 290-304		1
603	Atorvastatin plus omega-3 fatty acid ethyl ester decreases very-low-density lipoprotein triglyceride production in insulin resistant obese men. 2014 , 16, 519-26		8
602	Effect of omega-3 fatty acid supplementation on cancer incidence, non-vascular death, and total mortality: a meta-analysis of randomized controlled trials. 2014 , 14, 204		26
601	Atorvastatin combined with poly-unsaturated fatty acid confers better improvement of dyslipidemia and endothelium function. 2014 , 13, 186		6

600	Dietary fatty acids in health and disease: greater controversy, greater interest. 2014 , 17, 111-5	7
599	Supplementation of omega-3 polyunsaturated fatty acids prevents increase in arterial stiffness after experimental menopause. 2014 , 19, 114-20	11
598	HIV infection and cardiovascular disease. 2014 , 35, 1373-81	144
597	Clinical trial evidence and use of fish oil supplements. 2014 , 174, 460-2	36
596	Overview of prescription omega-3 fatty acid products for hypertriglyceridemia. 2014 , 126, 7-18	50
595	Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor. 2014 , 13, 159	116
594	Protective effects of dietary PUFA against chronic disease: evidence from epidemiological studies and intervention trials. 2014 , 73, 73-9	27
593	ELOVL2 gene polymorphisms are associated with increases in plasma eicosapentaenoic and docosahexaenoic acid proportions after fish oil supplement. 2014 , 9, 362	26
592	Documenting the global burden of cardiovascular disease: a major achievement but still a work in progress. 2014 , 129, 1459-62	15
591	Residual macrovascular risk in 2013: what have we learned?. 2014 , 13, 26	124
590	Cross-sectional and longitudinal associations of circulating omega-3 and omega-6 fatty acids with lipoprotein particle concentrations and sizes: population-based cohort study with 6-year follow-up. 2014 , 13, 28	8
589	Omega-3 fatty acids: a growing ocean of choices. 2014 , 16, 389	17
588	Cardiometabolic impact of non-statin lipid lowering therapies. 2014 , 16, 390	5
587	Emerging Lipoprotein-Related Therapeutics for Patients with Diabetes. 2014 , 435-453	
586	Biomarkers of fish oil omega-3 polyunsaturated fatty acids intake in humans. 2014 , 29, 63-72	26
585	Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3). 2014 , 100 Suppl 2, ii1-ii67	34 ^o
584	Limited impact of omega-3 fatty acids in patients with multiple cardiovascular risk factors. 2014 , 19, 18	1
583	An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia--full report. 2014 , 8, 29-60	246

582	"Fishing" for the origins of the "Eskimos and heart disease" story: facts or wishful thinking?. 2014 , 30, 864-8	49
581	Effects of Omega-3 fatty acid on major cardiovascular events and mortality in patients with coronary heart disease: a meta-analysis of randomized controlled trials. 2014 , 24, 470-5	67
580	Dietary fats and cardiovascular disease: putting together the pieces of a complicated puzzle. 2014 , 234, 320-8	137
579	Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial. 2014 , 57, 1325-31	39
578	Dietary n-3 PUFA and CVD: a review of the evidence. 2014 , 73, 57-64	54
577	EB fatty acids, atherosclerosis progression and cardiovascular outcomes in recent trials: new pieces in a complex puzzle. 2014 , 100, 530-3	41
576	Emerging drugs for hyperlipidaemia: an update. 2014 , 19, 471-88	5
575	The evidence for linolenic acid and cardiovascular disease benefits: Comparisons with eicosapentaenoic acid and docosahexaenoic acid. 2014 , 5, 863S-76S	69
574	Omega-3 fatty acids and cardiovascular disease: epidemiology and effects on cardiometabolic risk factors. 2014 , 5, 2004-19	46
573	Omega-3 fatty acids and the genetic risk of early onset acute coronary syndrome. 2014 , 24, 1234-9	8
572	Congenital lipodystrophies and dyslipidemias. 2014 , 16, 437	14
571	Dietary fat composition and cardiac events in patients with type 2 diabetes. 2014 , 236, 31-8	8
570	Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance. 2014 , 349, g4356	177
569	Very long chain omega-3 (n-3) fatty acids and human health. 2014 , 116, 1280-1300	159
568	LDL cholesterol: controversies and future therapeutic directions. 2014 , 384, 607-617	181
567	Nutrition for the prevention and treatment of chronic kidney disease in diabetes. 2014 , 38, 344-8	19
566	Diabetic dyslipidemia. 2014 , 63, 1469-79	226
565	Diabetes und Ernährung. 2014 , 10, 390-395	

564	Interaction between a CSK gene variant and fish oil intake influences blood pressure in healthy adults. 2014 , 144, 267-72	12
563	Lipid-lowering therapies, glucose control and incident diabetes: evidence, mechanisms and clinical implications. 2014 , 28, 361-77	29
562	The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. 2014 , 37, 1360-6	67
561	Standards of medical care in diabetes--2014. 2014 , 37 Suppl 1, S14-80	3373
560	Plant compared with marine n-3 fatty acid effects on cardiovascular risk factors and outcomes: what is the verdict?. 2014 , 100 Suppl 1, 453S-8S	13
559	Dietary supplementation with Lovaza and krill oil shortens the life span of long-lived F1 mice. 2014 , 36, 9659	16
558	Genetic predisposition scores for dyslipidaemia influence plasma lipid concentrations at baseline, but not the changes after controlled intake of n-3 polyunsaturated fatty acids. 2014 , 9, 412	5
557	Long-chain omega-3 fatty acids and cardiovascular health. 2014 , 13, 49-60	5
556	Add-on ezetimibe reduces small dense low-density lipoprotein cholesterol levels without affecting absorption of eicosapentaenoic acid in patients with coronary artery disease: a pilot study. 2014 , 14, 387-92	3
555	Linoleate appears to protect against palmitate-induced inflammation in Huh7 cells. 2014 , 13, 78	11
554	The limited effect of omega-3 polyunsaturated fatty acids on cardiovascular risk in patients with impaired glucose metabolism: a meta-analysis. 2014 , 47, 369-77	14
553	The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia. 2014 , 28, 369-85	23
552	Intake of total omega-3 fatty acids, eicosapentaenoic acid and docosahexaenoic acid and risk of coronary heart disease in the Spanish EPIC cohort study. 2014 , 24, 321-7	11
551	Cardiovascular disease in diabetes mellitus: risk factors and medical therapy. <i>Endocrinology and Metabolism Clinics of North America</i> , 2014 , 43, 25-40	5-5 33
550	Combination therapy of eicosapentaenoic acid and pitavastatin for coronary plaque regression evaluated by integrated backscatter intravascular ultrasonography (CHERRY study)-rationale and design. 2014 , 64, 236-9	8
549	Effects of a fish-based diet and administration of pure eicosapentaenoic acid on brachial-ankle pulse wave velocity in patients with cardiovascular risk factors. 2014 , 63, 211-7	10
548	Omega-3 and prostate cancer: examining the pertinent evidence. 2014 , 89, 444-50	11
547	Prevention and management of type 2 diabetes: dietary components and nutritional strategies. 2014 , 383, 1999-2007	655

546	The effect of nutritional supplements on serum high-density lipoprotein cholesterol and apolipoprotein A-I. 2014 , 14, 253-74		12
545	Critical review of non-statin treatments for dyslipoproteinemia. 2014 , 12, 359-71		5
544	Loss-of-function mutations in APOC3, triglycerides, and coronary disease. <i>New England Journal of Medicine</i> , 2014 , 371, 22-31	59.2	721
543	[HDL, or non-HDL: that is the question. Possibilities of pharmacological treatment in residual dyslipidaemia]. 2014 , 155, 62-8		
542	2014 Meet-The-Professor: Endocrine Case Management. 2014 ,		
541	Evidence-Based Guideline of the German Nutrition Society: Fat Intake and Prevention of Selected Nutrition-Related Diseases. 2015 , 67, 141-204		43
540	2015 Meet-The-Professor: Endocrine Case Management. 2015 ,		
539	Fatty acids linked to cardiovascular mortality are associated with risk factors. 2015 , 74, 28055		36
538	Baseline diabetes as a way to predict CV outcomes in a lipid-modifying trial: a meta-analysis of 330,376 patients from 47 landmark studies. 2015 , 14, 60		3
537	Improving the odds: ezetimibe and cardiovascular disease. 2015 , 69, 390-5		2
536	Effects of omega-3 fatty acids on arterial stiffness in patients with hypertension: a randomized pilot study. 2015 , 14, 21		11
535	EB Fatty Acids and Cardiovascular Diseases: Effects, Mechanisms and Dietary Relevance. 2015 , 16, 22636-61		73
534	Position paper FADOI sulla prevenzione cardiovascolare nei pazienti complessi a rischio. 2015 , 3, 309		
533	Choosing Healthy Fats. 2015 , 16, 205		
532	Combination pharmacotherapy in lipid management. 2015 , 58, 745		
531	Commonly Used Dietary Supplements on Coagulation Function during Surgery. 2015 , 2, 157-185		34
530	Interaction between Glucose and Lipid Metabolism: More than Diabetic Dyslipidemia. <i>Diabetes and Metabolism Journal</i> , 2015 , 39, 353-62	5	168
529	Plasma Fatty Acids in Zambian Adults with HIV/AIDS: Relation to Dietary Intake and Cardiovascular Risk Factors. 2015 , 2015, 635817		4

528	Omega-3 Polyunsaturated Fatty Acids: The Way Forward in Times of Mixed Evidence. 2015 , 2015, 143109	54
527	Beneficial effects of omega-3 polyunsaturated Fatty acids in gestational diabetes: consequences in macrosomia and adulthood obesity. 2015 , 2015, 731434	22
526	Il ruolo degli omega-3 nel paziente pluripatologico complesso: dalle evidenze alla pratica clinica in Medicina Interna. 2015 , 3, 241	
525	Cardioprotective Role of Omega-3 Polyunsaturated Fatty Acids Through the Regulation of Lipid Metabolism. 2015 , 563-588	0
524	Retrospective Case Series of Patients with Diabetes or Prediabetes Who Were Switched from Omega-3-Acid Ethyl Esters to Icosapent Ethyl. 2015 , 4, 83-93	16
523	Recent findings of long-chain n-3 polyunsaturated fatty acids (LCn-3 PUFAs) on atherosclerosis and coronary heart disease (CHD) contrasting studies in Western countries to Japan. 2015 , 25, 717-23	16
522	Saroglitazar for the treatment of dyslipidemia in diabetic patients. 2015 , 16, 597-606	47
521	Omega-3 fatty acids for breast cancer prevention and survivorship. 2015 , 17, 62	149
520	Hypertension and Dyslipidemia in Patients with Pre-Diabetes: Dietary and Other Therapies. 2015 , 157-179	
519	National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. 2015 , 9, S1-122.e1	293
518	The past, present and future of lipid-lowering therapy. 2015 , 10, 481-498	2
517	Type 2 diabetes mellitus, metabolic syndrome, and mixed dyslipidemia: how similar, how different, and how to treat?. 2015 , 13, 1-21	21
516	Diet Modification After Acute Coronary Events. 2015 , 323-334	
515	Statins: An Update on Clinical Issues and Selected Adverse Effects. 2015 , 11, 287-294	2
514	(4) Foundations of care: education, nutrition, physical activity, smoking cessation, psychosocial care, and immunization. 2015 , 38 Suppl, S20-30	173
513	Current drug treatment of hyperlipidemia in older adults. 2015 , 32, 127-38	10
512	Lipid Management. 2015 ,	1
511	Baroreflex sensitivity and central hemodynamics after omega-3 polyunsaturated fatty acids supplementation in an animal model of menopause. 2015 , 71, 65-9	8

510	Effect of dietary Fatty acids on human lipoprotein metabolism: a comprehensive update. 2015 , 7, 4416-25	83
509	Weighing Up Fish and Omega-3 PUFA Advice with Accurate, Balanced Scales: Stringent Controls and Measures Required for Clinical Trials. 2015 , 24, 740-3	8
508	Over-the-counter fish oil use in a county hospital: Medication use evaluation and efficacy analysis. 2015 , 9, 326-33	2
507	Current Treatment of Dyslipidemia: Evolving Roles of Non-Statins and Newer Drugs. 2015 , 75, 1201-28	15
506	The association between marine n-3 polyunsaturated fatty acid levels and survival after renal transplantation. 2015 , 10, 1246-56	34
505	Continuous decline in mortality from coronary heart disease in Japan despite a continuous and marked rise in total cholesterol: Japanese experience after the Seven Countries Study. 2015 , 44, 1614-24	20
504	Endogenously generated omega-3 fatty acids attenuate vascular inflammation and neointimal hyperplasia by interaction with free fatty acid receptor 4 in mice. 2015 , 4,	29
503	Functional Roles of Fatty Acids and Their Effects on Human Health. 2015 , 39, 18S-32S	410
502	Risk Prediction for Early CKD in Type 2 Diabetes. 2015 , 10, 1371-9	66
501	LDL, HDL, VLDL, and CVD Prevention: Lessons from Genetics?. 2015 , 17, 610	7
500	Nutraceuticals for the treatment of metabolic diseases: evidence from clinical practice. 2015 , 10, 297-304	7
499	Glycemic control for macrovascular disease in type II diabetes: Evidence and insights from recent trials. 2015 , 5, S83-S94	
498	[Accidental finding: hypertriglyceridemia]. 2015 , 157, 50-2	
497	Hypertriglyceridemia in an outpatient department--Significance as an atherosclerotic risk factor. 2015 , 18, 146-53	1
496	Some nutritional supplements may have modest beneficial effects on lipid levels, but the effects of most are negligible. 2015 , 31, 133-136	1
495	Medical Management of Serum Lipids and Coronary Heart Disease. 2015 , 39-55	
494	Management of hypertriglyceridemia for prevention of atherosclerotic cardiovascular disease. 2015 , 33, 309-23	11
493	Drug therapy of diabetic dyslipidemia: do the statins suffice?. 2015 , 22, 87-8	3

492	Colorectal cancer prevention and fishful thinking. 2015 , 107,	2
491	Indications for Omega-3 Long Chain Polyunsaturated Fatty Acid in the Prevention and Treatment of Cardiovascular Disease. 2015 , 24, 769-79	102
490	Strategies for improving cardiovascular health in women with diabetes mellitus: a review of the evidence. 2015 , 15, 98	1
489	Nonstatin therapies for management of dyslipidemia: a review. 2015 , 37, 2153-79	29
488	The Role of Omega-3 Fatty Acids in Dyslipidemias. 2015 , 45-64	1
487	Dyslipidemia in Obesity. 2015 , 1-18	
486	Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis. 2015 , 242, 357-66	114
485	Identifying Novel Biomarkers for Cardiovascular Events or Death in People With Dysglycemia. 2015 , 132, 2297-304	49
484	Type 2 Diabetes Mellitus and Dyslipidemia. 2015 , 99-113	1
483	From alga to omega; have we reached peak (fish) oil?. 2015 , 108, 351-7	5
482	Intake of polyunsaturated fat in relation to mortality among statin users and non-users in the Southern Community Cohort Study. 2015 , 25, 1016-24	8
481	Higher omega-3 index is associated with increased insulin sensitivity and more favourable metabolic profile in middle-aged overweight men. 2014 , 4, 6697	55
480	The association between dietary omega-3 fatty acids and cardiovascular death: the Singapore Chinese Health Study. 2015 , 22, 364-72	37
479	Complications of Diabetes Mellitus. 2016 , 1484-1581	11
478	Prescription omega-3 fatty acid products: considerations for patients with diabetes mellitus. 2016 , 9, 109-18	10
477	Nutraceuticals and Bioactive Components from Fish for Dyslipidemia and Cardiovascular Risk Reduction. 2016 , 14,	28
476	Fish and Fish Oil for Cardiovascular Disease in Diabetes. 2016 , 217-229	2
475	Fish, Fish Oil, and Liver Cancer. 2016 , 249-262	

474	. 2016,	2
473	Effect of n-3 Polyunsaturated Fatty Acids on Regression of Coronary Atherosclerosis in Statin Treated Patients Undergoing Percutaneous Coronary Intervention. 2016 , 46, 481-9	7
472	Lipids in Coronary Heart Disease. 2016 , 67-80	
471	Impact of Genotype on EPA and DHA Status and Responsiveness to Increased Intakes. 2016 , 8, 123	38
470	Effects of treatment of NAFLD on the metabolic syndrome. 2016 , 189-195	
469	Update on the treatment of type 2 diabetes mellitus. 2016 , 7, 354-95	269
468	Omega-3 Fatty Acids and Risk for Cardiovascular Disease. 2016 , 199-205	
467	Dietary Patterns and Insulin Resistance. 2016 , 19-28	
466	Statin Use Mitigate the Benefit of Omega-3 Fatty Acids Supplementation-A Meta-Regression of Randomized Trials. 2016 , 23, e737-48	8
465	Effects of eicosapentaenoic acid and docosahexaenoic acid on lipoproteins in hypertriglyceridemia. 2016 , 23, 145-9	9
464	Gene-diet interaction of a common FADS1 variant with marine polyunsaturated fatty acids for fatty acid composition in plasma and erythrocytes among men. 2016 , 60, 381-9	17
463	Red blood cell oleic acid levels reflect olive oil intake while omega-3 levels reflect fish intake and the use of omega-3 acid ethyl esters: The Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Heart Failure trial. 2016 , 36, 989-994	23
462	CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. 2016 , 22, 84-113	333
461	Diabetic Dyslipidemia and Risk of Cardiovascular Disease. 2016 , 643-652	
460	¿Cuáles son las novedades en nutrición para adultos con diabetes?. 2016 , 33, 18-23	
459	Lifestyle Interventions Including Nutrition, Exercise, and Supplements for Nonalcoholic Fatty Liver Disease in Children. 2016 , 61, 1375-86	60
458	Diabetic dyslipidaemia. 2016 , 27, 313-22	35
457	Managing dyslipidaemia in type 2 diabetes mellitus. 2016 , 30, 431-44	10

456	Global survey of the omega-3 fatty acids, docosahexaenoic acid and eicosapentaenoic acid in the blood stream of healthy adults. 2016 , 63, 132-52	284
455	Cardioprotective effect of resveratrol analogue isorhapontigenin versus omega-3 fatty acids in isoproterenol-induced myocardial infarction in rats. 2016 , 72, 469-84	36
454	Investigation of membrane fatty acid profiles in erythrocytes of patients with stable coronary artery disease. 2016 , 10, 930-936	2
453	Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism. 2016 , 12, 467-84	22
452	Conducting omega-3 clinical trials with cardiovascular outcomes: Proceedings of a workshop held at ISSFAL 2014. 2016 , 107, 30-42	40
451	Diabetes Dyslipidemia. 2016 , 7, 203-19	171
450	Statin combination therapy and cardiovascular risk reduction. 2016 , 12, 289-315	9
449	Marine omega-3 highly unsaturated fatty acids: From mechanisms to clinical implications in heart failure and arrhythmias. 2016 , 82, 11-9	12
448	Omega-3 polyunsaturated fatty acid supplementation in the prevention of cardiovascular disease. 2016 , 149, 166-73	24
447	Nutrient reference value: non-communicable disease endpoints--a conference report. 2016 , 55 Suppl 1, S1-10	15
446	Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products. 2016 , 16, 229-239	32
445	Lipoxygenases in Inflammation. 2016 ,	2
444	Dietary supplements and disease prevention - a global overview. 2016 , 12, 407-20	100
443	Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling. 2016 , 30, 2792-801	85
442	DISLIPIDEMIA DIABÉTICA. 2016 , 27, 152-159	4
441	Effects of sardine-enriched diet on metabolic control, inflammation and gut microbiota in drug-naïve patients with type 2 diabetes: a pilot randomized trial. 2016 , 15, 78	71
440	Tratamiento de la diabetes mellitus (I). 2016 , 12, 1001-1012	0
439	Effects of Omega-3 Fatty Acids in Myocardial Infarction. 2016 , 465-473	

438	Nutrition in Type 2 Diabetes and the Metabolic Syndrome. 2016 , 100, 1285-1302	20
437	[Impact of lipid metabolism parameters on the development and progression of coronary artery disease : An update]. 2016 , 41, 273-80	3
436	Progressing Insights into the Role of Dietary Fats in the Prevention of Cardiovascular Disease. 2016 , 18, 111	43
435	RBC omega-3 predicts risk for death. 2016 , 252, 192-193	1
434	Daily Intake of Milk Enriched with n-3 Fatty Acids, Oleic Acid, and Calcium Improves Metabolic and Bone Biomarkers in Postmenopausal Women. 2016 , 35, 529-536	25
433	Eicosapentaenoic acid ameliorates hyperglycemia in high-fat diet-sensitive diabetes mice in conjunction with restoration of hypo adiponectinemia. 2016 , 6, e213	4
432	Non-HDL Cholesterol and Triglycerides: Implications for Coronary Atheroma Progression and Clinical Events. 2016 , 36, 2220-2228	86
431	Triglyceride Treatment in the Age of Cholesterol Reduction. 2016 , 59, 107-118	9
430	Polymorphisms in FADS1 and FADS2 alter plasma fatty acids and desaturase levels in type 2 diabetic patients with coronary artery disease. 2016 , 14, 79	20
429	Creating the Future of Evidence-Based Nutrition Recommendations: Case Studies from Lipid Research. 2016 , 7, 747-55	4
428	Fish consumption, fish oils, and cardiovascular events: still waiting for definitive evidence. 2016 , 104, 951-952	3
427	2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. 2016 , 32, 1263-1282	543
426	Comparative analysis of the efficacy of omega-3 fatty acids for hypertriglyceridaemia management in Korea. 2016 , 41, 508-14	1
425	Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes. 2016 , 1858, 3131-3140	81
424	An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques. 2016 , 7, 12859	221
423	The emerging role of apolipoprotein C-III: beyond effects on triglyceride metabolism. 2016 , 15, 184	33
422	Omega-3 Fatty Acids and Cardiovascular Disease: Are There Benefits?. 2016 , 18, 69	107
421	What's new in nutrition for adults with diabetes?. 2016 , 47, 24-9	

420	The future of n-3 polyunsaturated fatty acid therapy. 2016 , 27, 570-578		13
419	Aktuelle Lipidtherapie bei Diabetes mellitus. 2016 , 12, 80-87		
418	Controversies in omega-3 efficacy and novel concepts for application. 2016 , 5, 11-22		19
417	Dietary fried fish intake increases risk of CVD: the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. 2016 , 19, 3327-3336		27
416	Whole Blood Ω 3 Fatty Acids Are Inversely Associated with Carotid Intima-Media Thickness in Indigenous Mexican Women. 2016 , 146, 1365-72		7
415	A novel cost-effectiveness model of prescription eicosapentaenoic acid extrapolated to secondary prevention of cardiovascular diseases in the United States. 2016 , 19, 1003-10		4
414	Baseline characteristics of participants in the VITamin D and OmegA-3 Trial (VITAL). 2016 , 47, 235-43		76
413	3. Foundations of Care and Comprehensive Medical Evaluation. 2016 , 39 Suppl 1, S23-35		125
412	History and future of omega-3 fatty acids in cardiovascular disease. 2016 , 32, 301-11		22
411	Surprises From Genetic Analyses of Lipid Risk Factors for Atherosclerosis. 2016 , 118, 579-85		98
410	Management of Hypertriglyceridemia for Prevention of Atherosclerotic Cardiovascular Disease. <i>Endocrinology and Metabolism Clinics of North America</i> , 2016 , 45, 185-204	5.5	17
409	Dyslipidemia in Obesity. 2016 , 525-540		1
408	What's new in nutrition for adults with diabetes?. 2016 , 46, 28-33; quiz 33-4		6
407	Plasma levels of marine n-3 fatty acids and cardiovascular risk markers in renal transplant recipients. 2016 , 70, 824-30		11
406	Reincarnated medicines: using out-dated drugs for novel indications. 2016 , 37, 2571-6		5
405	Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE). 2016 , 39, 709-16		48
404	From Heart Failure to Highly Unsaturated Fatty Acid Deficiency and Vice Versa: Bidirectional Heart and Liver Interactions. 2016 , 32, 217-25		6
403	Lipoprotein Metabolism and the Treatment of Lipid Disorders. 2016 , 715-736.e7		3

402	Longitudinal associations of serum fatty acid composition with type 2 diabetes risk and markers of insulin secretion and sensitivity in the Finnish Diabetes Prevention Study. 2016 , 55, 967-79	47
401	Update on the Vitamin D and Omega-3 trial (VITAL). 2016 , 155, 252-6	64
400	Red blood cell polyunsaturated fatty acids and mortality in the Women's Health Initiative Memory Study. 2017 , 11, 250-259.e5	45
399	A Meta-Analysis of Randomized Controlled Trials and Prospective Cohort Studies of Eicosapentaenoic and Docosahexaenoic Long-Chain Omega-3 Fatty Acids and Coronary Heart Disease Risk. 2017 , 92, 15-29	158
398	Omega-3 fatty acids predict recurrent venous thromboembolism or total mortality in elderly patients with acute venous thromboembolism. 2017 , 15, 47-56	16
397	The pro- or antiarrhythmic actions of polyunsaturated fatty acids and of cholesterol. 2017 , 176, 40-47	7
396	Does Supplementation with Omega-3 PUFAs Add to the Prevention of Cardiovascular Disease?. 2017 , 19, 47	20
395	Impact of Hypertriglyceridemia on Carotid Stenosis Progression under Normal Low-Density Lipoprotein Cholesterol Levels. 2017 , 26, 1793-1800	7
394	How important are triglycerides as risk factors?. 2017 , 18 Suppl 1, e7-e12	1
393	Insulin Resistance and Diabetes Associated with Lipodystrophies. 2017 , 119-133	
392	Notes. 2017 , 209-228	
391	Effect of omega-3 supplementation on neuropathy in type 1 diabetes: A 12-month pilot trial. 2017 , 88, 2294-2301	68
390	Boosting Inflammation Resolution in Atherosclerosis: The Next Frontier for Therapy. 2017 , 187, 1211-1221	108
389	Dietary Intake of Omega-3 Fatty Acids From Fish and Risk of Diabetic Retinopathy. 2017 , 317, 2226-2227	7
388	Omega-3 polyunsaturated fatty acids for cardiovascular diseases: present, past and future. 2017 , 10, 865-873	49
387	TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS. 2017 , 23, 100-112	32
386	CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY. 2017 , 23, 207-238	302
385	Omega-3 Polyunsaturated Fatty Acid (Fish Oil) Supplementation and the Prevention of Clinical Cardiovascular Disease: A Science Advisory From the American Heart Association. 2017 , 135, e867-e884	371

384	Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial. 2017 , 40, 138-148	114
383	Omega-3 fatty acid fish oil dietary supplements contain saturated fats and oxidized lipids that may interfere with their intended biological benefits. 2017 , 483, 425-429	61
382	Ω-Polyunsaturated fatty acids for heart failure: Effects of dose on efficacy and novel signaling through free fatty acid receptor 4. 2017 , 103, 74-92	40
381	4. Lifestyle Management. 2017 , 40, S33-S43	208
380	Marine OMEGA-3 fatty acids in the prevention of cardiovascular disease. 2017 , 123, 51-58	54
379	Effects of fish oil-derived fatty acids on suboptimal cardiovascular health: A multicenter, randomized, double-blind, placebo-controlled trial. 2017 , 27, 964-970	4
378	Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study. 2017 , 130, 1465.e27-1465.e39	10
377	What's New in Nutrition for Adults With Diabetes?. 2017 , 35, 386-390	1
376	Diabetes Update 2017 <i>Lipide</i> . 2017 , 13, 313-321	1
375	ApoCIII enrichment in HDL impairs HDL-mediated cholesterol efflux capacity. 2017 , 7, 2312	34
374	Nutrition therapy for diabetes: Implications for decreasing cardiovascular complications. 2017 , 31, 1477-1480	2
373	Use of supplemental long-chain omega-3 fatty acids and risk for cardiac death: An updated meta-analysis and review of research gaps. 2017 , 11, 1152-1160.e2	69
372	Effect of insulin glargine on recreational physical activity and TV viewing: Analysis of the randomised ORIGIN trial. 2017 , 132, 137-143	
371	Effects of Oxidative Stress, Hyperglycemia, and Hypercholesterolemia on Membrane Structural Organization and the Interactions of Omega-3 Fatty Acids. 2017 , 31-47	0
370	Omega-3 fatty acids in atherosclerosis and coronary artery disease. 2017 , 3, FSO236	26
369	Review of Cardiometabolic Effects of Prescription Omega-3 Fatty Acids. 2017 , 19, 60	26
368	Docosahexaenoic acid regulates vascular endothelial cell function and prevents cardiovascular disease. 2017 , 16, 118	42
367	Cancer risks of anti-hyperglycemic drugs for type 2 diabetes treatment - a clinical appraisal. 2017 , 31, 1451-1457	2

366	Treatment with high-dose n-3 PUFAs has no effect on platelet function, coagulation, metabolic status or inflammation in patients with atherosclerosis and type 2 diabetes. 2017 , 16, 50	59
365	Fit with good fat? The role of n-3 polyunsaturated fatty acids on exercise performance. 2017 , 66, 45-54	39
364	Impact of omega-3 polyunsaturated fatty acids on vascular function and blood pressure: Relevance for cardiovascular outcomes. 2017 , 27, 191-200	89
363	Cardioprotective effects of omega 3 fatty acids: origin of the variability. 2017 , 38, 25-30	7
362	Cardiovascular disease and omega-3s: Prescription products and fish oil dietary supplements are not the same. 2017 , 29, 791-801	4
361	Managing hypertriglyceridemia: What can we learn from cardiovascular outcomes trials?. 2017 , 42 Suppl 12, 3-9	1
360	Relationship between n-3 Polyunsaturated Fatty Acids and Extent of Vessel Disease in Patients with ST Elevation Myocardial Infarction. 2017 , 58, 868-873	6
359	Precision Nutrition and Omega-3 Polyunsaturated Fatty Acids: A Case for Personalized Supplementation Approaches for the Prevention and Management of Human Diseases. 2017 , 9,	58
358	Effects of Omega-3 Long Chain Polyunsaturated Fatty Acid Supplementation on Cardiovascular Mortality: The Importance of the Dose of DHA. 2017 , 9,	27
357	A novel self-micro-emulsifying delivery system (SMEDS) formulation significantly improves the fasting absorption of EPA and DHA from a single dose of an omega-3 ethyl ester concentrate. 2017 , 16, 204	17
356	New evidence that omega-3 fatty acids have a role in primary prevention of coronary heart disease. 2017 , 1, 35-35	14
355	Erythrocyte long-chain omega-3 fatty acid levels are inversely associated with mortality and with incident cardiovascular disease: The Framingham Heart Study. 2018 , 12, 718-727.e6	66
354	Modulation of miRNA expression in aged rat hippocampus by buttermilk and krill oil. 2018 , 8, 3993	12
353	Blood HER2 and Uromodulin as Causal Mediators of CKD. 2018 , 29, 1326-1335	14
352	Abnormal Myocardial Dietary Fatty Acid Metabolism and Diabetic Cardiomyopathy. 2018 , 34, 605-614	32
351	Nutrition Therapy. 2018 , 42 Suppl 1, S64-S79	57
350	Reprint of: Marine OMEGA-3 fatty acids in the prevention of cardiovascular disease. 2018 , 126, 8-15	6
349	Nutraceuticals as therapeutic agents for atherosclerosis. 2018 , 1864, 1562-1572	47

348	Elevated triglycerides and low high-density lipoprotein cholesterol level as marker of very high risk in type 2 diabetes. 2018 , 25, 118-129	20
347	Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77 917 Individuals. 2018 , 3, 225-234	403
346	Omega-3 Polyunsaturated Fatty Acids and Their Health Benefits. 2018 , 9, 345-381	366
345	Hypertension with diabetes mellitus complications. 2018 , 41, 147-156	43
344	Serum Ω 3 Polyunsaturated Fatty Acids and Potential Influence Factors in Elderly Patients with Multiple Cardiovascular Risk Factors. 2018 , 8, 1102	7
343	Hypertriglyceridemia and omega-3 fatty acids: Their often overlooked role in cardiovascular disease prevention. 2018 , 28, 197-205	24
342	Lipids. 2018 , 359-385	
341	Vitamins and Dietary Supplements for the Older Adult: What Works and Why?. 2018 , 25, e173-e182	
340	Dietary management of dyslipidaemias. Is there any evidence for cardiovascular benefit?. 2018 , 108, 45-52	16
339	New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk. 2018 , 4, 119-127	11
338	Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Health: A Comprehensive Review. 2018 , 61, 76-85	44
337	The role of omega-3 polyunsaturated fatty acid supplementation in the management of type 2 diabetes mellitus: A narrative review. 2018 , 14, 42-51	22
336	Bioactive compounds as an alternative for drug co-therapy: Overcoming challenges in cardiovascular disease prevention. 2018 , 58, 958-971	19
335	Basic Mechanisms of Atherosclerosis. 2018 , 45-54	2
334	Eicosapentaenoic acid and docosahexaenoic acid containing supplements modulate risk factors for cardiovascular disease: a meta-analysis of randomised placebo-control human clinical trials. 2018 , 31, 67-84	58
333	Very long-chain n-3 fatty acids and human health: fact, fiction and the future. 2018 , 77, 52-72	174
332	2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. 2018 , 15, e73-e188	151
331	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. 2018 , 138, e272-e381	307

330	The cardiovascular benefits of indiscriminate supplementation of omega-3 fatty acids; meta-analysis and decision-making approach. 2018 , 69, 549-556	3
329	4. Lifestyle Management:. 2018 , 41, S38-S50	391
328	Unsolved Antiatherogenic Mechanism of n-3 Polyunsaturated Fatty Acids. 2018 , 82, 332-333	2
327	Effect and safety of combination lipid-lowering therapies based on statin treatment versus statin monotherapies on patients with high risk of cardiovascular events. 2018 , 1, 176-184	0
326	Cost-Effectiveness of Statin Plus Eicosapentaenoic Acid Combination Therapy for Cardiovascular Disease Prevention in Japanese Patients With Hypercholesterolemia - An Analysis Based on the Japan Eicosapentaenoic Acid Lipid Intervention Study (JELIS). 2018 , 82, 1076-1082	6
325	Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. 2018 , 11, CD003177	89
324	Cardiovascular Disease and Risk Management: Review of the American Diabetes Association Standards of Medical Care in Diabetes 2018. 2018 , 168, 640-650	48
323	An Improvement of Cardiovascular Risk Factors by Omega-3 Polyunsaturated Fatty Acids. 2018 , 10, 281-289	41
322	The role of non-resolving inflammation in atherosclerosis. 2018 , 128, 2713-2723	117
321	. 2018 ,	1
320	Fish, Fish Oils and Cardioprotection: Promise or Fish Tale?. 2018 , 19,	30
319	Baseline levels of serum high sensitivity C reactive protein and lipids in predicting the residual risk of cardiovascular events in Chinese population with stable coronary artery disease: a prospective cohort study. 2018 , 17, 273	5
318	Functional Metabolomics Characterizes a Key Role for -Acetylneuraminic Acid in Coronary Artery Diseases. 2018 , 137, 1374-1390	76
317	[Lipidology - important changes of the last 10 years]. 2018 , 160, 42-44	
316	GOALS FOR MEDICAL TREATMENT IN OBESITY AND PREDIABETES: IMPROVING OUTCOMES FOR BOTH. 2018 , 24, 1093-1098	0
315	High-dose omega-3 fatty acids have no effect on platelet aggregation or coagulation measured with static and flow-based aggregation instruments and Sonoclot; an observational study in healthy volunteers. 2018 , 78, 539-545	10
314	Association of Serum Triglycerides With Arterial Stiffness in Subjects With Low Levels of Low-Density Lipoprotein Cholesterol. 2018 , 82, 3052-3057	5
313	Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial. 2018 , 41, 2404-2413	16

312 Genetics of Coronary Atherosclerosis. **2018**, 33-44

311 Dose-response effects of omega-3 on platelet aggregation: an observational study. **2018**, 46, 5074-5082 1

310 Macrophage Trafficking, Inflammatory Resolution, and Genomics in Atherosclerosis: JACC Macrophage in CVD Series (Part 2). **2018**, 72, 2181-2197 76

309 Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017. **2018**, 25, 846-984 295

308 Eicosapentaenoic acid improves endothelial function and nitric oxide bioavailability in a manner that is enhanced in combination with a statin. **2018**, 103, 1231-1237 39

307 Elevated plasma lipoprotein(a) levels were associated with increased risk of cardiovascular events in Chinese patients with stable coronary artery disease. **2018**, 8, 7726 21

306 A high omega-3 fatty acid diet rapidly changes the lipid composition of cardiac tissue and results in cardioprotection. **2018**, 96, 916-921 7

305 Hypertriglyceridemia in Diabetes Mellitus: Implications for Pediatric Care. **2018**, 2, 497-512 15

304 Lipids and Lipoprotein Mediators of Endothelial Function and Dysfunction. **2018**, 285-296

303 Effects of Mediterranean Diet on Endothelial Function. **2018**, 363-389 1

302 Nitro-fatty acids: New drug candidates for chronic inflammatory and fibrotic diseases. **2018**, 79, 31-37 49

301 Cardioprotective Effects of Omega-3 Polyunsaturated Fatty Acids: Dichotomy between Experimental and Clinical Studies. **2018**, 16, 12

300 CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY. **2018**, 24, 91-120 321

299 Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. **2018**, 7, CD003177 112

298 Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease. **2018**, 7, CD012345 39

297 Cardiovascular Risk Assessment in Patients with Hypertriglyceridemia. **2018**, 20, 71

296 Fish consumption is associated with a decreased risk of death among adults with diabetes: 18-year follow-up of a national cohort. **2018**, 28, 1012-1020 13

295 Relationship between polyunsaturated fatty acid composition in serum phospholipids, systemic low-grade inflammation, and glycemic control in patients with type 2 diabetes and atherosclerotic cardiovascular disease. **2018**, 17, 29 17

294	Metabolites as regulators of insulin sensitivity and metabolism. 2018 , 19, 654-672		167
293	Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus. <i>New England Journal of Medicine</i> , 2018 , 379, 1540-1550	59.2	338
292	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. 2018 , 72, e91-e220		411
291	Dry Eye Assessment and Management (DREAM [®]) Study: Study design and baseline characteristics. 2018 , 71, 70-79		27
290	Association of blood levels of marine omega-3 fatty acids with coronary calcification and calcium density in Japanese men. 2019 , 73, 783-792		13
289	A low-fat spread with added plant sterols and fish omega-3 fatty acids lowers serum triglyceride and LDL-cholesterol concentrations in individuals with modest hypercholesterolaemia and hypertriglyceridaemia. 2019 , 58, 1615-1624		15
288	Omega-3, omega-6, and total dietary polyunsaturated fat for prevention and treatment of type 2 diabetes mellitus: systematic review and meta-analysis of randomised controlled trials. 2019 , 366, l4697		89
287	Diabetes and Atherogenic Dyslipidemia. 2019 , 587-596		1
286	Access to clinical trial data-Commentary. 2019 , 16, 552-554		
285	Omega-3 Fatty Acids and the Cardiovascular System. 2019 , 213-228		
284	Effects of Fish n-3 PUFAs on Intestinal Microbiota and Immune System. 2019 , 17,		46
283	Rounding the corner on residual risk: Implications of REDUCE-IT for omega-3 polyunsaturated fatty acids treatment in secondary prevention of atherosclerotic cardiovascular disease. 2019 , 42, 829		9
282	Dietary fats and mortality among patients with type 2 diabetes: analysis in two population based cohort studies. 2019 , 366, l4009		25
281	Diabetic Cardiac Autonomic Neuropathy. 2019 , 825-850		2
280	National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. 2019 , 13, 860-872		49
279	Addition of marine omega-3 fatty acids to statins in familial hypercholesterolemia does not affect in vivo or in vitro endothelial function. 2019 , 13, 762-770		5
278	Effect of High-Dose Marine Omega-3 Fatty Acids on Atherosclerosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. 2019 , 11,		15
277	Omega-3 Polyunsaturated Fatty Acids and Stroke Burden. 2019 , 20,		8

276	Marine-Derived Omega-3 Polyunsaturated Fatty Acids and Heart Failure: Current Understanding for Basic to Clinical Relevance. 2019 , 20,	28
275	Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials. 2019 , 140, 1308-1317	85
274	Marine Omega-3 Supplementation and Cardiovascular Disease: An Updated Meta-Analysis of 13 Randomized Controlled Trials Involving 127 477 Participants. 2019 , 8, e013543	150
273	A Novel Anti-Inflammatory Role of Omega-3 PUFAs in Prevention and Treatment of Atherosclerosis and Vascular Cognitive Impairment and Dementia. 2019 , 11,	47
272	Management of diabetic dyslipidemia: An update. 2019 , 10, 280-290	26
271	Insights into the cardioprotective properties of n-3 PUFAs against ischemic heart disease via modulation of the innate immune system. 2019 , 308, 20-44	26
270	Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report. 2019 , 42, 731-754	356
269	Clinical Advances in Immunonutrition and Atherosclerosis: A Review. 2019 , 10, 837	39
268	Serum triglycerides as a risk factor for cardiovascular diseases in type 2 diabetes mellitus: a systematic review and meta-analysis of prospective studies. 2019 , 18, 48	33
267	-3 Fatty acids and risk for fatal coronary disease. 2019 , 78, 526-531	5
266	An omega-3 fatty acid plasma index $\geq 4\%$ prevents progression of coronary artery plaque in patients with coronary artery disease on statin treatment. 2019 , 285, 153-162	15
265	Is Grassfed Meat and Dairy Better for Human and Environmental Health?. 2019 , 6, 26	31
264	Evidence-Based Cardiovascular Risk Management in Diabetes. 2019 , 19, 439-448	5
263	Effects of basal insulin glargine and omega-3 on lower limb arterial disease outcome in patients with dysglycaemia: An analysis of the Outcome Reduction with an Initial Glargine INtervention (ORIGIN) trial. 2019 , 21, 1502-1505	1
262	Triglycerides: Emerging Targets in Diabetes Care? Review of Moderate Hypertriglyceridemia in Diabetes. 2019 , 19, 13	14
261	Nutritional Management of Diabetes: A Critical Review. 2019 , 289-308	1
260	CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY. 2019 , 25, 69-100	191
259	5. Lifestyle Management:. 2019 , 42, S46-S60	346

258	Diabetes: Omega-3-Fettsäuren schützen nicht vor Herz-Kreislauf-Erkrankungen. 2019 , 44, 91-92		
257	Editorial: Omega-3 fatty acids and cardiovascular outcomes: an update. 2019 , 22, 97-102		4
256	The association of basal insulin treatment versus standard care with outcomes in anti-GAD positive and negative subjects: A post-hoc analysis of the ORIGIN trial. 2019 , 21, 429-433		2
255	Prevention is back in the spotlight - Highlights from American Heart Association Scientific Sessions 2018. 2019 , 26, 502-506		
254	Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs. 2019 , 19, 113-131		2
253	Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. <i>New England Journal of Medicine</i> , 2019 , 380, 23-32	59.2	438
252	Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. <i>New England Journal of Medicine</i> , 2019 , 380, 11-22	59.2	1316
251	Drug Therapy of Dyslipidemia in the Elderly. 2019 , 36, 321-340		13
250	Omega-3 Fatty Acid and Cardiovascular Outcomes: Insights From Recent Clinical Trials. 2019 , 21, 1		23
249	Supplements. 2019 , 11, 100-101		
248	Polyunsaturated Fatty Acids and Atherosclerosis: Insights from Pre-Clinical Studies. 2019 , 121, 1800029		12
247	The Effect of Omega-3 Fatty Acids, EPA, and/or DHA on Male Infertility: A Systematic Review and Meta-analysis. 2019 , 16, 245-256		31
246	The Role of n-3 Fatty Acids in Cardiovascular Disease: Back to the Future. 2020 , 71, 10-16		17
245	Omega-3 supplement use, fish intake, and risk of non-fatal coronary artery disease and ischemic stroke in the Million Veteran Program. 2020 , 39, 574-579		4
244	Prevention of Cardiovascular Events with Omega-3 Polyunsaturated Fatty Acids and the Mechanism Involved. 2020 , 27, 183-198		20
243	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. 2020 , 41, 255-323		1360
242	Dietary and Pharmacological Fatty Acids and Cardiovascular Health. 2020 , 105,		11
241	Marine-derived n-3 fatty acids therapy for stroke. 2019 , 6, CD012815		4

240	Risk of cardiovascular events in patients with hypertriglyceridaemia: A review of real-world evidence. 2020 , 22, 279-289	19
239	Vitamin D, Marine n-3 Fatty Acids, and Primary Prevention of Cardiovascular Disease Current Evidence. 2020 , 126, 112-128	25
238	A case-based approach to integrative medicine for cardiovascular disease prevention. 2020 , 18, 159-162	1
237	A combination of Omega-3 PUFAs and COX inhibitors: A novel strategy to manage obesity-linked dyslipidemia and adipose tissue inflammation. 2020 , 34, 107494	5
236	The Mediterranean Diet Slows Down the Progression of Aging and Helps to Prevent the Onset of Frailty: A Narrative Review. 2019 , 12,	35
235	Current Concepts in Management of Lipid Abnormalities in Patients With Coronary Artery Disease. 2020 , 1, 164-173	
234	Very Long Chain Marine -3 Polyunsaturated Fatty Acids in Atherothrombotic Heart Disease. A Brief Review, with a Focus on Metabolic Effects. 2020 , 12,	2
233	Long-term prognostic utility of low-density lipoprotein (LDL) triglyceride in real-world patients with coronary artery disease and diabetes or prediabetes. 2020 , 19, 152	5
232	The journey of omega-3 fatty acids in cardiovascular medicine. 2020 , 22, J49-J53	2
231	Management of hypertriglyceridemia. 2020 , 371, m3109	28
230	Coronary atherosclerotic plaque progression: contributing factors in statin-treated patients. 2020 , 18, 873-880	1
229	Prerandomization run-in periods in randomized controlled trials of chronic diseases: a methodological study. 2020 , 128, 148-156	1
228	Impact of Different Doses of Omega-3 Fatty Acids on Cardiovascular Outcomes: a Pairwise and Network Meta-analysis. 2020 , 22, 45	8
227	Fish in the Mediterranean diet. 2020 , 275-284	1
226	Roles for circulating polyunsaturated fatty acids in ischemic stroke and modifiable factors: a Mendelian randomization study. 2020 , 19, 70	6
225	Use of non-LDL-C lipid-lowering medications in patients with type 2 diabetes. 2020 , 3, e00126	1
224	VLDL Cholesterol Accounts for One-Half of the Risk of Myocardial Infarction Associated With apoB-Containing Lipoproteins. 2020 , 76, 2725-2735	35
223	Effects of Omega-3 Fatty Acids on Major Adverse Cardiovascular Events: What Matters Most: the Drug, the Dose, or the Placebo?. 2020 , 324, 2262-2264	19

222	Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. 2020 , 324, 2268-2280	209
221	Effects of Eicosapentaenoic Acid on Arterial Calcification. 2020 , 21,	2
220	Specialized pro-resolving lipid mediators in cardiovascular disease, diagnosis, and therapy. 2020 , 159, 170-179	7
219	Comparative Effect of Statins and Omega-3 Supplementation on Cardiovascular Events: Meta-Analysis and Network Meta-Analysis of 63 Randomized Controlled Trials Including 264,516 Participants. 2020 , 12,	6
218	5. Facilitating Behavior Change and Well-being to Improve Health Outcomes:. 2020 , 43, S48-S65	182
217	All-Cause Mortality and Cardiovascular Death between Statins and Omega-3 Supplementation: A Meta-Analysis and Network Meta-Analysis from 55 Randomized Controlled Trials. 2020 , 12,	2
216	Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline. 2020 , 105,	26
215	Cardiac Arrhythmia Prevention in Ischemia and Reperfusion by Low-Dose Dietary Fish Oil Supplementation in Rats. 2020 , 150, 3086-3093	8
214	Decreased plasma n6:n3 polyunsaturated fatty acids ratio interacting with high C-peptide promotes non-alcoholic fatty liver disease in type 2 diabetes patients. 2021 , 12, 1263-1271	1
213	Association between Iron Intake and Diabetic Peripheral Neuropathy in Type 2 Diabetes: Significance of Iron Intake and the Ratio between Iron Intake and Polyunsaturated Fatty Acids Intake. 2020 , 12,	1
212	Guía ESC 2019 sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes (EASD). 2020 , 73, 404.e1-404.e59	2
211	Prevalence of US Adults with Triglycerides \geq 50 mg/dl: NHANES 2007-2014. 2020 , 9, 207-213	20
210	The return of triglycerides and revival of omega-3 fatty acids!. 2020 , 113, 369-373	5
209	Genomics of hypertriglyceridemia. 2020 , 97, 141-169	3
208	Omega-3 for the prevention of cardiovascular diseases: meta-analysis and trial-sequential analysis. 2020 ,	1
207	Translating evidence from clinical trials of omega-3 fatty acids to clinical practice. 2020 , 16, 343-350	
206	Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid. 2020 , 69, 771-783	12
205	Defining the Role of Icosapent Ethyl in Clinical Practice. 2020 , 20, 517-524	1

204	Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes. 2020 , 141, 1360-1370	8
203	Triglycerides and Cardiovascular Outcomes-Can We REDUCE-IT ?. 2020 , 29, 2-11	1
202	Lipid management for cardiovascular risk reduction in type 1 diabetes. 2020 , 27, 207-214	6
201	Omega-3 polyunsaturated fatty acids supplementation and cardiovascular outcomes: do formulation, dosage, and baseline cardiovascular risk matter? An updated meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2020 , 160, 105060	10.2 11
200	Dietary treatment to lower cholesterol and triglyceride and reduce cardiovascular risk. 2020 , 31, 206-231	9
199	Emirates Diabetes Society Consensus Guidelines for the Management of Type 2 Diabetes Mellitus □ 2020 , 26, 1-20	4
198	Marine Omega-3 (N-3) Fatty Acids for Cardiovascular Health: An Update for 2020. 2020 , 21,	108
197	Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. 2020 , 3, CD003177	75
196	Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date. 2020 , 16, 1-10	7
195	The Rise and Fall "ing" of the HDL Hypothesis. 2020 , 80, 353-362	2
194	Effects of dietary n-3 polyunsaturated fatty acids on cardiovascular disease. 2020 , 64, 217-240	2
193	Inflammation and cardiovascular disease: are marine phospholipids the answer?. 2020 , 11, 2861-2885	39
192	CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM -. 2020 , 26, 107-139	206
191	Effects of an Omega-3 and Vitamin D Supplement on Fatty Acids and Vitamin D Serum Levels in Double-Blinded, Randomized, Controlled Trials in Healthy and Crohn's Disease Populations. 2020 , 12,	3
190	Short-Term Efficacy (at 12 Weeks) and Long-Term Safety (up to 52 Weeks) of Omega-3 Free Fatty Acids (AZD0585) for the Treatment of Japanese Patients With Dyslipidemia - A Randomized, Double-Blind, Placebo-Controlled, Phase III Study. 2020 , 84, 994-1003	2
189	Reducing Cardiovascular Disease Risk in Women Beyond Statin Therapy: New Insights 2020. 2020 , 29, 1091-1100	5
188	Diet, Lifestyle and Cardiovascular Diseases: Linking Pathophysiology to Cardioprotective Effects of Natural Bioactive Compounds. 2020 , 17,	77
187	Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses. 2021 , 143, 33-44	25

186	Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction: A Randomized, Controlled Trial. 2021 , 143, 528-539	73
185	Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids: JACC Focus Seminar. 2021 , 77, 593-608	10
184	Omega-3 polyunsaturated fatty acids focusing on eicosapentaenoic acid and docosahexaenoic acid in the prevention of cardiovascular diseases: a review of the state-of-the-art. 2021 , 14, 79-93	7
183	Omega-3 supplementation and cardiovascular disease: formulation-based systematic review and meta-analysis with trial sequential analysis. 2021 , 107, 150-158	14
182	Intake of fish and long-chain n-3 polyunsaturated fatty acids and risk of diseases in a Japanese population: a narrative review. 2021 , 75, 902-920	1
181	Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction. 2021 , 17, 155-174	7
180	Does polymorphisms in and genes modify associations between fatty acid desaturase (Δ 5), Δ -6 long-chain PUFA and cardiometabolic markers in 8-11-year-old Danish children?. 2021 , 125, 369-376	0
179	Position Statement on Fat Consumption and Cardiovascular Health - 2021. 2021 , 116, 160-212	4
178	Omega-3 nutraceuticals, climate change and threats to the environment: The cases of Antarctic krill and <i>Calanus finmarchicus</i> . 2021 , 50, 1184-1199	2
177	Apolipoprotein C-III and cardiovascular diseases: when genetics meet molecular pathologies. 2021 , 48, 875-886	4
176	Microbiota, a New Playground for the Omega-3 Polyunsaturated Fatty Acids in Cardiovascular Diseases. 2021 , 19,	4
175	Dietary fatty acids and CHD: from specific recommendations to dietary patterns. 2021 , 34, 240-258	2
174	The importance of omega fatty acids for the prevention of cardiovascular disease. 2021 , 24, 90	
173	Health benefits of omega-3 fatty acids. 2021 , 25-53	0
172	From Fish Waste to Value: An Overview of the Sustainable Recovery of Omega-3 for Food Supplements. 2021 , 26,	25
171	Effects and Issues of Diet Fat on Cardiovascular Metabolism.	
170	Purposeful Review to Identify the Benefits, Mechanism of Action and Practical Considerations of Omega-3 Polyunsaturated Fatty Acid Supplementation for the Management of Diabetes Mellitus. Volume 13, 53-65	1
169	Cardiovascular Disease Risk Reduction in Mild-Moderate Hypertriglyceridemia: Integrating Prescription of Omega-3 with Standard Treatment. 2021 , 23, 27	3

168	The ratio of eicosapentaenoic acid to docosahexaenoic acid as a modulator for the cardio-metabolic effects of omega-3 supplements: A meta-regression of randomized clinical trials. 2021 , 57, 102662	2
167	Plasma Omega-3 Fatty Acids and the Risk of Cardiovascular Events in Patients After an Acute Coronary Syndrome in MERLIN-TIMI 36. 2021 , 10, e017401	6
166	Effects of omega-3 fatty acids, vitamins, and chelation therapy in patients with heart diseases. 2021 , 18, 1-10	
165	A new era for preventive cardiology. 2021 ,	
164	The role of icosapent ethyl in cardiovascular risk reduction. 2021 , 36, 661-671	0
163	Cardiovascular effects of omega-3 fatty acids: Hope or hype?. 2021 , 322, 15-23	8
162	Associations of Fish Consumption With Risk of Cardiovascular Disease and Mortality Among Individuals With or Without Vascular Disease From 58 Countries. 2021 , 181, 631-649	17
161	Omega-3 fatty acids ameliorate vascular inflammation: A rationale for their atheroprotective effects. 2021 , 324, 27-37	9
160	New Trends in Dyslipidemia Treatment. 2021 , 85, 759-768	4
159	Dyslipidemia Management in 2020: An Update on Diagnosis and Therapeutic Perspectives. 2021 , 21, 815-834	4
158	Role of polyunsaturated fatty acids in ischemic stroke - A perspective of specialized pro-resolving mediators. 2021 , 40, 2974-2987	5
157	Omega-3 Fatty Acids and Coronary Artery Disease: More Questions Than Answers. 2021 , 10,	3
156	Omega-3 Supplementation and Heart Disease: A Population-Based Diet by Gene Analysis of Clinical Trial Outcomes. 2021 , 13,	1
155	Triglyceride-lowering and anti-inflammatory mechanisms of omega-3 polyunsaturated fatty acids for atherosclerotic cardiovascular risk reduction. 2021 , 15, 556-568	2
154	Omega-3 Fatty Acids and Cardiovascular Disease: A Narrative Review for Pharmacists. 2021 , 26, 524-532	1
153	Update on the omega-3 fatty acid trial landscape: A narrative review with implications for primary prevention. 2021 , 15, 545-555	5
152	Association between ANGPTL3, 4, and 8 and lipid and glucose metabolism markers in patients with diabetes. 2021 , 16, e0255147	1
151	NT-proBNP versus routine clinical risk factors as a predictor of cardiovascular events or death in people with dysglycemia - A brief report from the ORIGIN trial. 2021 , 35, 107928	1

150	Latin American Consensus on management of residual cardiometabolic risk. A consensus paper prepared by the Latin American Academy for the Study of Lipids and Cardiometabolic Risk (ALALIP) endorsed by the Inter-American Society of Cardiology (IASC), the International Atherosclerosis Society (IAS), and the Pan-American College of Endothelium (PACE). 2021 ,	1
149	[Omega-3 Polyunsaturated Fatty Acids in Patients with Hypertriglyceridemias and Atherosclerosis]. 2021 , 61, 88-96	1
148	Omega-3 supplementation and heart failure: A meta-analysis of 12 trials including 81,364 participants. 2021 , 107, 106458	3
147	Association Between Achieved Ω Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk: A Secondary Analysis of the STRENGTH Trial. 2021 ,	13
146	2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. 2021 , 37, 1129-1150	62
145	Vascepa protects against high-fat diet-induced glucose intolerance, insulin resistance, and impaired β cell function. 2021 , 24, 102909	2
144	Omega-3 fatty acids for the prevention of atherosclerotic cardiovascular disease. 2021 ,	3
143	Diabetic dyslipidaemia. 2021 , 26, e00248	1
142	Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis. 2021 , 38, 100997	21
141	Emerging agents for the treatment and prevention of stroke: progress in clinical trials. 2021 , 30, 1025-1035	2
140	Is Coffee the Cause or the Cure? Conflicting Nutrition Messages in Two Decades of Online Nutrition News Coverage. 2021 , 1-15	0
139	Comparative efficacy of pharmacological agents on reducing the risk of major adverse cardiovascular events in the hypertriglyceridemia population: a network meta-analysis. 2021 , 13, 15	3
138	The Influence of Eicosapentaenoic Acid to Arachidonic Acid Ratio on Long-term Cardiovascular Events Following Percutaneous Coronary Intervention. 2021 ,	0
137	Highlights from Studies Presented at the American Heart Association Scientific Session 2020: Navigating New Roads in Prevention. 2021 , 23, 4	5
136	Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease. 2018 , 11, CD012345	23
135	Diabetes Mellitus and Chronic Kidney Disease (Stages 1 β). 2014 , 103-136	1
134	Lifestyle Interventions for Primary and Secondary Prevention of Cardiovascular Disease. 2015 , 1695-1718	1
133	Omega-3, Omega-6, and Polyunsaturated Fat for Cognition: Systematic Review and Meta-analysis of Randomized Trials. 2020 , 21, 1439-1450.e21	20

132	Intake and metabolism of omega-3 and omega-6 polyunsaturated fatty acids: nutritional implications for cardiometabolic diseases. 2020 , 8, 915-930	35
131	Pro-resolving lipid mediators in vascular disease. 2018 , 128, 3727-3735	33
130	Effect of fish oil supplementation on fasting vascular endothelial function in humans: a meta-analysis of randomized controlled trials. 2012 , 7, e46028	44
129	Baseline plasma fatty acids profile and incident cardiovascular events in the SU.FOL.OM3 trial: the evidence revisited. 2014 , 9, e92548	14
128	Fish-Free Diet in Patients with Phenylketonuria Is Not Associated with Early Atherosclerotic Changes and Enhanced Platelet Activation. 2015 , 10, e0135930	4
127	Protective activities of distinct omega-3 enriched oils are linked to their ability to upregulate specialized pro-resolving mediators. 2020 , 15, e0242543	2
126	Recent Clinical Trials Shed New Light on the Cardiovascular Benefits of Omega-3 Fatty Acids. 2019 , 15, 171-178	26
125	[The effect of long-chain polyunsaturated ω fatty acids on the arterial stiffness parameters in patients with diabetes mellitus type 2 and cardiovascular autonomic neuropathy]. 2015 , 115, 80-84	2
124	Concerning the Depression of ω 3 polyunsaturated fatty acids by adepts of evidence-based medicine. 2019 , 12, 91-114	8
123	Atherogenic dyslipidemia and combination pharmacotherapy in diabetes: recent clinical trials. 2013 , 10, 191-203	9
122	Is There Something Fishy About Fish Oil?. 2019 , 25, 1747-1759	3
121	Dietary Fish Oil Concentrates Associated Health Benefits: A Recent Development of Cardiovascular Risk Reduction. 2019 , 25, 4053-4062	2
120	Prevention of Endothelial Dysfunction and Cardiovascular Disease by n-3 Fatty Acids-Inhibiting Action on Oxidative Stress and Inflammation. 2020 , 26, 3652-3666	3
119	Phase 4 Studies in Heart Failure - What is Done and What is Needed?. 2016 , 12, 216-30	12
118	5. Facilitating Behavior Change and Well-being to Improve Health Outcomes:. 2021 , 44, S53-S72	93
117	The Treatment of Disorders of Lipid Metabolism. 2016 , 113, 261-8	40
116	The effect of n-3 fatty acids on glucose homeostasis and insulin sensitivity. 2014 , 63, S93-118	106
115	Determination of fatty acid composition content in the herbal antidiabetic collections. 2020 , 67, 153-159	5

114	Fibrates Revisited: Potential Role in Cardiovascular Risk Reduction. <i>Diabetes and Metabolism Journal</i> , 2020 , 44, 213-221	5	10
113	Origin and therapy for hypertriglyceridaemia in type 2 diabetes. 2014 , 5, 165-75		11
112	Diabetic cardiac autonomic neuropathy: Do we have any treatment perspectives?. 2015 , 6, 245-58		20
111	Effects of polyunsaturated fatty acids on periprocedural myocardial infarction after elective percutaneous coronary intervention. 2014 , 10, 792-8		8
110	Cost-effectiveness analysis of highly concentrated n-3 polyunsaturated fatty acids in secondary prevention after myocardial infarction. 2017 , 9, 21-30		2
109	Is the Effect of Omega-3 Polyunsaturated Fatty Acids Dependent on Life-Style, Severity of Disease, and Use of Concomitant Medications?. 2017 , 24, 256-257		1
108	Cost-Utility Analysis of Dapagliflozin Compared to Sulfonylureas for Type 2 Diabetes as Second-Line Treatment in Indian Healthcare Payer's Perspective. 2021 , 13, 897-907		0
107	Residual Cardiovascular Risk Factors in Dyslipidemia.		
106	Triglyceride Levels and Residual Risk of Atherosclerotic Cardiovascular Disease Events and Death in Adults Receiving Statin Therapy for Primary or Secondary Prevention: Insights From the KP REACH Study. 2021 , 10, e020377		3
105	Perioperative parenteral fish oil supplementation improves postoperative coagulation function and outcomes in patients undergoing colectomy for ulcerative colitis. 2021 ,		
104	[Omega-3 fatty acids--both food and medicine]. 2012 , 132, 2258		0
103	[Early insulin therapy in type 2 diabetes?]. 2012 , 132, 2151-2		1
102	Ernährungstherapie des Typ-2-Diabetes.		
101	Fettstoffwechsel und Hypertonie bei Diabetes. 2014 , 217-237		
100	Lifestyle Interventions for Primary and Secondary Prevention of Cardiovascular Disease. 2014 , 1-29		
99	Die Diabetologische Schwerpunktpraxis [Aufgaben und Versorgungsauftrag. 2014 , 333-339		
98	Non-Statins Treatment of Dyslipidemia. 2015 , 201-231		
97	N-3 Fatty Acids: Role in Treating Dyslipidemias and Preventing Cardiovascular Disease. 2015 , 355-370		

- 96 n-3 and n-6 Fatty Acids Reduce Risk for Cardiovascular Disease. **2015**, 255-271
- 95 Update on the Pharmacologic Agents for Dyslipidemia. **2015**, 16, 269
- 94 Lipoxygenases and Cardiovascular Diseases. **2016**, 101-130 1
- 93 Content of Some Pro- and Anti-inflammatory Factors, Insulin Resistance Parameters in Patients with Type 2 Diabetes Mellitus and Cardiovascular Autonomic Neuropathy, Influence of Omega-3 Polyunsaturated Fatty Acids on These Parameters. **2017**, 2-3, 32-38
- 92 Wie definiert man Gesundheit?. **2018**, 29-31
- 91 What should interventional cardiologists do for patients with prediabetes?. **2018**, 14, e968-e970
- 90 Clasificaci3n de los desenlaces en los ensayos cl3nicos. **2019**, 38, 147-157 0
- 89 Dietary Supplementation with Anti-Inflammatory Omega-3 Fatty Acids for Cardiovascular Protection: Help or Hoax?. **2019**, 7, 78-85 1
- 88 2. Pathophysiology of Atherosclerosis and Its Prevention and Treatment. **2019**, 108, 96a-103a
- 87 The Influence of Unsaturated Fatty Acids for Atherosclerosis in Recent Years. **2019**, 9-11
- 86 Acides gras om^ ga^3 ^longue cha^ne et risque cardiovasculaire, revue critique. **2019**, 15, 14-20
- 85 2. Pathophysiology of Atherosclerosis and Its Prevention and Treatment. **2019**, 108, 1685-1699
- 84 [Association of polyunsaturated fatty acids treatment with coronary mortality. A meta-analysis]. **2019**, 59, 63-68
- 83 Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG. **2021**, 144, 1845-1855 10
- 82 Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL. **2021**, 144, 1750-1759 8
- 81 Management of Hypertriglyceridemia (Including Fibrates and n-3 Fatty Acids). **2021**, 295-306
- 80 Marine n-3 fatty acid consumption in a Norwegian renal transplant cohort: Comparison of a food frequency questionnaire with plasma phospholipid marine n-3 levels. **2020**, 15, e0244089
- 79 Ersonified diagnostic and correction dyslipidemia approach by profiling of apolipoproteins. **2020**, 88-104

78	Optimal Dose of n-3 Polyunsaturated Fatty Acids for Cardiovascular Event Prevention. 2020 , 2, 260-264	0
77	Are Statins the Optimal Therapy for Cardiovascular Risk in Patients with Diabetes? What Newer Agents Are There for the Treatment for Dyslipidemia in Diabetes? Are Triglycerides an Important Risk Factor for Diabetes?. 2021 , 198-210	
76	Omega-3 for patients with cardiovascular disease. 2012 , 58, 1225	
75	Overview of omega-3 Fatty Acid therapies. 2013 , 38, 681-91	62
74	A Comparative Overview of Prescription Omega-3 Fatty Acid Products. 2015 , 40, 826-57	20
73	Integrative Therapies and Cardiovascular Disease in the Breast Cancer Population: A Review, Part 2. 2015 , 14, 33-40	1
72	Omega-3 polyunsaturated fatty acids for the prevention of cardiovascular disease: do formulation, dosage & comparator matter?. 2013 , 110, 495-8	3
71	Comparison of Cardiovascular Outcomes Between Statin Monotherapy and Fish Oil and Statin Combination Therapy in a Veteran Population. 2018 , 35, 26-31	
70	Mechanisms underlying diabetic cardiomyopathy: From pathophysiology to novel therapeutic targets. 2020 , 3, 82-97	2
69	Effects of omega-3 polyunsaturated fatty acids supplementation for patients with cardiovascular disease risks: a dose-response meta-analysis. 2021 , 13, 8526-8539	
68	Effects of polyunsaturated fatty acid rich diets and risk of non-communicable diseases. 2022 , 165-185	
67	PUFA, genotypes and risk for cardiovascular disease.. 2021 , 176, 102377	0
66	Effect of Omega-3 Fatty Acids on Coronary Plaque Morphology - A Serial Computed Tomography Angiography Study. 2021 ,	2
65	EPIDEMIOLOGY OF THE MOST COMMON RISK FACTORS CAUSING THE DEVELOPMENT OF BLOOD CIRCULATION DISEASES AND THEIR CONTRIBUTION TO MORTALITY OF MALE ABLE-BODIED POPULATION. 2018 , 8-15	2
64	Fat-1 expression alleviates atherosclerosis in transgenic rabbits.. 2022 ,	1
63	The Effects of Fish Oil on Cardiovascular Diseases: Systematical Evaluation and Recent Advance.. 2021 , 8, 802306	7
62	Role of EPA in Inflammation: Mechanisms, Effects, and Clinical Relevance.. 2022 , 12,	4
61	Omega-3 Fatty Acid Supplementation and Coronary Heart Disease Risks: A Meta-Analysis of Randomized Controlled Clinical Trials.. 2022 , 9, 809311	1

60	Omega-3 Polyunsaturated Fatty Acids-Vascular and Cardiac Effects on the Cellular and Molecular Level (Narrative Review).. 2022 , 23,	3
59	Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI.. 2022 , e022937	3
58	Inflammatory Links Between Hypertriglyceridemia and Atherogenesis.. 2022 , 1	2
57	Diet and Nutrition in Peripheral Artery Disease: A Systematic Review.. 2022 ,	1
56	N-3 polyunsaturated fatty acids for cardiovascular risk.. 2022 ,	0
55	Methylene-bridge tryptophan fatty acylation regulates PI3K-AKT signaling and glucose uptake.. 2022 , 38, 110509	
54	Diabetes Mellitus, Race, and Effects of Omega-3 Fatty Acids on Incidence of Heart Failure Hospitalization.. 2022 , 10, 227-234	0
53	Dose-related meta-analysis for Omega-3 fatty acids supplementation on major adverse cardiovascular events.. 2022 , 41, 923-930	0
52	Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid.. 2022 , 237, 108172	2
51	5. Facilitating Behavior Change and Well-being to Improve Health Outcomes: Standards of Medical Care in Diabetes-2022.. 2022 , 45, S60-S82	24
50	Approach to patients with hypertriglyceridemia.. 2022 , 101659	1
49	Highly Purified Eicosapentaenoic Acid Alleviates the Inflammatory Response and Oxidative Stress in Macrophages during Atherosclerosis via the miR-1a-3p/sFRP1/Wnt/PCP-JNK Pathway.. 2022 , 2022, 9451058	2
48	The Effects of Omega-3 Supplementation on Depression in Adults with Cardiometabolic Disease: A Systematic Review of Randomised Control Trials.. 2022 , 14,	
47	Precision Medicine for Diabetes and Dyslipidemia. 2022 , 65-87	
46	Health Benefits, Food Applications, and Sustainability of MI-Croalgae-Derived N-3 Pufa. 2022 , 11, 1883	3
45	Marine Nutraceuticals. 2022 , 105-112	
44	Marine-derived n-3 fatty acids therapy for stroke. 2022 , 2022,	
43	Tratamiento de la hipertrigliceridemia con icosapento de etilo en pacientes de alto/muy alto riesgo cardiovascular. Documento de consenso de la Sociedad Española de Cardiología y Sociedad Española de Diabetes. <i>Endocrinología, Diabetes Y Nutrición</i> , 2022 ,	1.3 0

42	Big Fish or No Fish; Eicosapentaenoic Acid and Cardiovascular Disease. <i>Endocrinology and Metabolism Clinics of North America</i> , 2022 ,	5.5	0
41	Omega-3 and cardiovascular prevention [Is this still a choice?]. <i>Pharmacological Research</i> , 2022 , 182, 106342.2	4.2	2
40	Triglyceride-Rich Lipoproteins, Remnants, and Atherosclerotic Cardiovascular Disease Risk. <i>Current Cardiovascular Risk Reports</i> ,	0.9	
39	New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins. <i>Diabetes and Metabolism Journal</i> , 2022 , 46, 517-532	5	0
38	Fasting triglycerides are positively associated with cardiovascular mortality risk in people with diabetes.		0
37	Eicosapentaenoic Acid for Cardiovascular Events Reduction- Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. 2022 ,		
36	Plasma fingerprint of free fatty acids and their correlations with the traditional cardiac biomarkers in patients with type 2 diabetes complicated by coronary heart disease. 9,		1
35	Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements. 2022 , 20, 609-625		0
34	Effects of omega-3 fatty acid on major cardiovascular outcomes: A systematic review and meta-analysis. 2022 , 101, e29556		0
33	The role of selected nutraceuticals in management of prediabetes and diabetes: An updated review of the literature.		1
32	Habitual fish oil supplementation and the risk of incident atrial fibrillation: Findings from a large prospective longitudinal cohort study..		0
31	Efficacy and Safety of Omega-3 Fatty Acids in the Prevention of Cardiovascular Disease: A Systematic Review and Meta-analysis.		0
30	Clinical significance of polyunsaturated fatty acids in the prevention of cardiovascular diseases. 9,		0
29	Comparative efficacy of omega-3 polyunsaturated fatty acids on major cardiovascular events: A network meta-analysis of randomized controlled trials. 2022 , 88, 101196		0
28	Role of natural fatty acids in prophylaxis and treatment of cardiovascular diseases. 2022 , 68, 27-35		0
27	Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad Española de Cardiología [Spanish Society of Cardiology] and the Sociedad Española de Diabetes [Spanish Diabetes Society]. 2022 ,		0
26	Cardiovascular outcomes of ethyl eicosapentaenoic acid in diabetes mellitus: A meta-analysis. 2022 , 104846		0
25	Study Protocol and Baseline Characteristics of Randomized Trial for Evaluating Secondary Prevention Efficacy of Combination Therapy Statin and Eicosapentaenoic Acid: RESPECT-EPA, The Combination of a Randomized Control Trial and an Observational Biomarker Study. 2022 ,		0

24	Marine omega-3 fatty acid supplementation and prevention of cardiovascular disease: update on the randomized trial evidence.	1
23	Study protocol of the PROUD48 study comparing the effects of pemafibrate and omega-3 fatty acid ethyl esters on ApoB-48 in statin-treated patients with dyslipidaemia: a prospective, multicentre, open-label, randomised, parallel group trial in Japan. 2022 , 12, e061360	0
22	Interaction among dietary n-3 and n-6 polyunsaturated fatty acid intake, fatty acid desaturase 2 genetic variants, and low-density lipoprotein cholesterol levels in type 2 diabetes patients.	0
21	Intakes of omega-3 fatty acids and risks of all-cause and cause-specific mortality in people with diabetes: a cohort study based on NHANES 1999-2014.	0
20	Are U-shaped relationships between risk factors and outcomes artifactual?. 2022 , 14, 815-821	0
19	5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes-2023. 2023 , 46, S68-S96	1
18	Role of omega-3 fatty acids in the prevention and treatment of cardiovascular Diseases: A consensus statement from the Experts Committee Of National Society Of Cardiometabolic Medicine. 13,	0
17	Permanenter Anstieg unserer Lebenserwartung. 2022 , 1-30	0
16	Classes of Lipid Mediators and Their Effects on Vascular Inflammation in Atherosclerosis. 2023 , 24, 1637	1
15	Imaging subclinical coronary atherosclerosis to guide lipid management, are we there yet?. 2023 , 13, 100451	0
14	The effects of pemafibrate and omega-3 fatty acid ethyl on apoB-48 in dyslipidemic patients treated with statin: A prospective, multicenter, open-label, randomized, parallel group trial in Japan (PROUD48 study). 10,	0
13	Pros and Cons of Long-Chain Omega-3 Polyunsaturated Fatty Acids in Cardiovascular Health. 2023 , 63, 383-406	1
12	The Potential Cardiometabolic Effects of Long-Chain Omega-3 Polyunsaturated Fatty Acids: Recent Updates and Controversies. 2023 ,	0
11	Thyroid Dysfunction and Cardiovascular Events in Patients With Dysglycemia. 2023 , 47, 257-262	0
10	Omega-3 Fatty Acids in Cardiovascular Disease and Diabetes: a Review of Recent Evidence. 2023 , 25, 51-65	0
9	Current and Emerging Therapies for Atherosclerotic Cardiovascular Disease Risk Reduction in Hypertriglyceridemia. 2023 , 12, 1382	0
8	Assessing the Highest Level of Evidence from Randomized Controlled Trials in Omega-3 Research. 2023 , 15, 1001	0
7	Saturated fatty acids increase LPI to reduce FUNDC1 dimerization and stability and mitochondrial function. 2023 , 24,	0

- 6 Benefits of omega-3 polyunsaturated fatty acids to patients with oral and metabolic diseases. **2023**, 10, 001-004
- 5 Eicosapentaenoic Acid Preserves Mitochondrial Quality and Attenuates Cardiac Remodeling After Myocardial Infarction in Rats.
- 4 Recent Trials on the Cardioprotective Effects of New Generation Anti-diabetic and Lipid-Lowering Agents. **2023**, 117-167
- 3 Omega-3 polyunsaturated fatty acids for the management of dyslipidemia and reduction of residual cardiovascular risk. **2023**, 124-137
- 2 Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. 14,
- 1 Wie definiert man Gesundheit?. **2022**, 31-33